Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04625725
Recruitment Status : Active, not recruiting
First Posted : November 12, 2020
Last Update Posted : November 11, 2021
Iqvia Pty Ltd
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : May 5, 2021
Estimated Study Completion Date : June 29, 2022
CDC. (Centers for Disease Control and Prevention). Coronavirus Disease 2019 (COVID-19), Symptoms of Coronavrus. Published 2020. Accessed 01 July 2020.
Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl Met al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. The Lancet Rheumatology. 2019;1(4):e208-e19.
Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213-26. Morand EF, Furie RA. Anifrolumab in Systemic Lupus Erythematosus. Reply. N Engl J Med. 2020;382(17):1666.
WHO. WHO Coronavirus Disease (COVID-19) Dashboard. 2020a.
WHO. WHO R&D Blueprint COVID-19 Therapeutic Trial Synopsis Draft 18 February 2020. Published 2020b. Accessed 25 September 2020.